Walter Lovenberg, Ph.D.
Director and Acting Chief Executive Officer
Dr. Walter Lovenberg is Acting CEO of QuantumBio and serves on the Board of Directors. He is also currently President of Lovenberg Associates, Inc. and a director of Merrimack Pharmaceuticals, Inc. Previously, he was a Director of OSI Pharmaceuticals, Inc. ( 1993-2006) and former director of several private biotechnology companies. Some of Dr. Lovenberg’s past positions include Executive Vice President and Board member of Marion Merrell Dow, Inc. where he was responsible for global research. Additionally, he was previously Chief of the Section of Biochemical Pharmacology at the National Institutes of Health. Dr. Lovenberg received a Ph.D. from George Washington University and is the author or co-author of over 300 scientific publications.
Walter C. Greenblatt, MBA
Walter Greenblatt has served as a director since ????. He currently is the Managing Director of Walter Greenblatt & Associates, a FINRA registered broker-dealer focusing exclusively on early stage life science companies located in Princeton, New Jersey. He utilizes his experience as a veteran lifescience-focused investment banker to raise seed capital and early institutional funding for fast-growing lifescience startups, which have included WuXi Pharmatech, MedAvante, Advanced BioHealing and many others in various therapeutic areas. In addition to raising early-stage capital, he closes M&A and business development transactions for clients developing therapeutics, medical devices and pharmaceutical services. Mr. Greenblatt is an experienced entrepreneur and “hands-on” operating executive himself, having founded, grown and sold a profitable business. Before that, he was with Bain & Company. Mr. Greenblatt received his MBA Harvard Business School with Distinction after graduating from Yale (summa cum laude). He also received a Masters in Economics with First Class Honours from Balliol College, Oxford University.
Kenneth M. Merz, Jr., Ph.D.
Director and Chief Scientific Officer
Dr. Merz is the Chief Scientific Officer and serves on the Board of Directors. He is currently the Colonel Allan R. and Margaret G. Crow Term Professor of Chemistry at the University of Florida and a Member and Co-Director of the Quantum Theory Project. His research interest is in the application of theoretical and computational tools to biological problems including drug design, mechanistic enzymology and protein folding. Prior to his current position, Dr. Merz was an Assistant, Associate, and Professor of Chemistry at the Pennsylvania State University from 1989-2005. He also has worked in industry (1998-2001) as the Senior Director of the Center for Informatics and Drug Discovery (CIDD) at Pharmacopeia, Inc. and as the Senior Director of the ADMET Research and Development Group in the Accelrys software division of Pharmacopeia. Dr. Merz is a recognized leader in the field of computational chemistry, publishing over 150 articles in peer-reviewed journals and giving more than 150 presentations worldwide. He has received a number of honors including the 2010 ACS Award for Computers in Chemical and Pharmaceutical Research, election as a fellow of the American Association for the Advancement of Science, a John Simon Guggenheim Fellowship and he has held visiting professorships at the Institute for Research in Biomedicine (Barcelona, Spain), École Polytechnique (Paris, France), University of Florence (Florence, Italy), The University of Strasbourg (Strasbourg, France), The University of Oviedo (Oviedo, Spain) and the ETH (Zurich, Switzerland). He received his BS from Washington College and his Ph.D. in Organic Chemistry from The University of Texas.
Jacquelyn S. Fetrow, PhD
Dr. Jacquelyn Fetrow has served as a director since ????. Dr. Fetrow holds the position of Dean of Wake Forest College and is the Reynolds Professor of Computational Biophysics at Wake Forest Univierstiy, with joint appointments in both the departments of physics and computer science. Dr. Fetrow also currently serves on the Executive Council of the Protein Society, an international professional organization. She, and one of her colleagues, won the 2006 Wake Forest Teaching and Learning Center Innovative Teaching Award for developing a bioinformatics software solution through an innovative course. Prior to her position at Wake Forest, Dr. Fetrow served as Chief Scientific Officer and Director of GeneFormatics, a biotechnology software company, for five years where she played a key role in developing company strategy, raising over $50 million in three funding rounds, building to a 65-person organization and merging of the company to another biotechnology software company in 2003. Dr. Fetrow co-invented GeneFormatics’ primary technologies and holds a US patent for those inventions. In previous positions, she served on the faculties of The Scripps Research Institute for two years and the University at Albany in New York for seven years. At Albany, she received both the Chancellor’s and President’s awards for excellence in teaching. Dr. Fetrow earned a Ph.D. in biological chemistry from Pennsylvania State University.
Stephen Carpenter, MBA
Stephen Carpenter was appointed to the Board in May 2008 and previously served as a board observer. He is the Vice President of Venture Operations at the Life Sciences Greenhouse of Central Pennsylvania. His principal responsibilities include serving as a director or board observer for portfolio companies and evaluating prospective companies for investment. Mr. Carpenter has over 20 years of leadership experience at DuPont, Berg Electronics, and FCI USA in a variety of engineering and management positions with a specific focus on new product launches and operation start-ups. Mr. Carpenter earned a BS in Mechanical Engineering from Lehigh University and an MBA from Penn State University where his academic concentration was on venture capital, entrepreneurship, and finance. Prior to joining the LSGPA, he led a State College start-up software company to profitability while completing his MBA.